Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes alopecia associated with escitalopram use, which improved upon switching to duloxetine, and examines existing literature on antidepressant-related hair loss.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

CTP-543 is generally safe for treating alopecia areata.

This study suggests that statins may help treat acute alopecia areata, with animal experiments showing increased regulatory T cell populations after statin treatment in mice with the condition.

This update provides information on new drug approvals but does not offer new clinical research findings.

This study reviews current treatments for PCOS and evaluates Tirzepatide as a potential option for its management, suggesting possible benefits for those with obesity and metabolic syndrome but not for those of normal weight.

This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

This case report details a probable severe adverse event associated with ritlecitinib for alopecia areata, highlighting risks of pulmonary emboli, infection, atrial fibrillation, and acute kidney injury despite an absence of known risk factors.

This report documented a case of thrombocytopenia and leukopenia linked to the long-term use of itraconazole in a patient with acute myelogenous leukemia.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.

This article describes cutaneous reactions including keratosis pilaris-like eruptions in a patient on nilotinib for chronic myelogenous leukemia, emphasizing the importance of accurately classifying such eruptions.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

This study reported the development of new pyrazole-based MPC inhibitors that effectively inhibit mitochondrial pyruvate transport, showing potential as therapeutic candidates for conditions like metabolic dysfunction-associated steatohepatitis without activating PPARγ.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

In this study, Deplanque et al. (2016) explored doxycycline's role in preventing erlotinib-induced folliculitis in patients with non-small-cell lung cancer, highlighting skin toxicity as a common side effect that can affect patient adherence to treatment.

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

In this study, analysis of electronic health records suggested that patients taking semaglutide were significantly less likely to experience suicidal ideation compared to those on non-GLP-1 obesity or diabetes medications.

This review discusses zinc supplementation as a complementary therapy for chronic hepatitis C, noting its potential benefits in improving treatment outcomes and reducing side effects, but reports no new clinical results.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

This article discusses the importance of increasing awareness about specific adverse drug reactions, prevention methods, and the promotion of reporting ADRs to the FDA's MEDWATCH program; it reports no new results.